Philip Nitschke, Australia’s Dr. Death, continues to promote the purchase of Nembutal, a drug used by veterinarians for euthanasia, through his website and “chatroom” to people who purchase his peaceful pill book. Read more

In the June – July, 2010 version of the Exit International newsletter Nitschke published an article – Nembutal by Mail: Online Trade in Barbituates. CONTACT US VIA [email protected]

In March I commented on a report from the Victorian Institute of Forensic Medicine of 51 people in Australia who died from lethal veterinary drugs.

51 people were known to have died from Nembutal, 6 people were in their 20’s, 8 people were in their 30’s, 5 people were in their 40’s, 14 people were in their 50’s, 3 people in their 60’s, 10 in their 70’s, and 5 people were over the age of 80.

Further to that, the report found that of the 38 known deaths that were investigated by a coroner, only 11 had a significant physical illness or chronic pain with the remaining 27 cases showing no signs of physical problems.

The report suggested that the 27 otherwise healthy people who died from Nembutal use were most likely depressed or mentally ill. Click here

From 1 May, Exit members will be able to purchase the Barbiturate Test Kit. The Kit will be available via Bitcoin at Developed within a philosophical framework of harm minimisation, the Exit Drug Test is a qualitative test, designed to establish the presence of sodium pentobarbital. That many Exit members and subscribers to the Peaceful Pill eHandbook have acquired Nembutal through a variety of means, and with some people finding themselves in possession of bottles without labels, a method of testing a suspect substance is the only responsible thing to do. The Exit Drug Test Kit comprises a buffer solution, test cassette, pipette, syringe (for extracting the test substance) and a pair of plastic gloves. The Kit will ship in a plain wrapper and Exit does not expect any issues with customs in any countries. While a positive result will not, at this stage, provide an indication of the strength of the tested liquid, it will provide peace of mind as to the identification of the liquid. Exit members will be able to place ad-vance orders at from 10 March in the knowledge that ship-ping commences 1 May 2010. Read more

An 89-year-old doctor, seriously ill, wrote this comment:

“I am reading Derek Humphry’s “Final Exit.” It is a wonderful book. It should be required reading in medical school. The topic should be discussed in medical school. The style reminds me of Dale Carnegie’s “How to Win Friends and Influence People,” my kind of book, clear thinking, easy to understand.” Our products list

World interest in self-deliverance ebook

May 13th, 2020 by ergo

Derek Humphry’s new ebook, “Final Exit 2020”
is getting response throughout the world. Orders for the download include customers from Moscow,
Zagreb, Oslo, Tokyo, Sydney, Paris and London.
Most of the orders are from North American people who want the updated version of the original l991 New York Times bestseller, the first book to describe self-deliverance from a terminal or hopeless illness. Profits from the ebook go to right-to-die organizations..
Visit the ERGO Bookstore at this secure site: Nembutal FAQ

What it’s like to be 90 years old…..

Apr 28th, 2020 by ergo

Wednesday, April 29, 2020

Reached 90 years old today!
Ninety! Through a combination of good luck (in the Blitz at age 10-11 etc), never smoking and good medical care. (Heart surgeries l997 and 2019.) Still mobile but slower. I Will press on and see how far it goes! About Nembutal

You all stay carefully safe and well in these troubled times.

World-wide interest in ‘Final Exit 2020’ ebook

Apr 19th, 2020 by ergo

Interest in reading my Ebook ‘Final Exit 2020’ has recently come from Tokyo, Moscow, Bejing, Norway and Australia. Not massively, but consistent. Obviously a deep interest.
Take a look at

Choices about medical care in case of the onset of the virus

Apr 7th, 2020 by ergo

Here is a document about CHOICES in the event of severe novel coronavirus illness. Think it over carefully. It is not legally enforceable but might be a useful guide to hospital staff.

April 2020
My Choices If I Become Sick
in the COVID Pandemic

Choose only one in each group of three.

MEDICAL FACILITY: I want to be transferred to a medical facility as soon as my symptoms
are not easily managed at home.

IT DEPENDS: I want to stay at home unless my symptoms cannot be adequately managed at
home, in which case I want to be transferred to a medical facility.

HOME: I want to stay at home, if possible, even if my distress becomes considerable.

Symptom Management

LOW: I want minimal sedation and want to be clear and conscious as long as possible.

MEDIUM: I want adequate sedation but would like to be clear and conscious enough to
communicate if possible.

HIGH: I want maximum treatment of my symptoms, including pain, and understand this
might hasten my death.

Life Support Machines (Including Ventilators)

If I become sick enough to need a life support machine…

YES: I want to be on a life support machine if one is available.

MAYBE: I would prefer to be on a life support machine, but do not want to be put on a life
support machine if there are others who are more likely to survive and need it.

NO: I do not want to be put on a life support machine even if one is available.

Bendigo Advertiser 8 May 2020
Young and physically healthy people are killing themselves using a drug recommended by euthanasia groups
The state government inquiry into end-of-life choices was told that 52 Victorians died using pentobarbitone, otherwise known as Nembutal or “the peaceful pill”, between 1999 and 2014.
Coroners Prevention Unit manager Jeremy Dwyer told the Legal and Social Issues Committee that the majority of those suicides were young people who were physically healthy, but mentally ill.
“There have been claims from the authors of The Peaceful Pill Handbook that their messages are only intended for one group [the elderly and seriously ill],” he said.
“But the unintended consequences of it is that people who are not the stated audience are picking up on it, they’re obtaining Pentobarbitone in the way recommended in The Peaceful Pill Handbook and Exit International material and they’re suiciding.
“That group used to be the minority, now it’s the majority of Pentobarbitone suicides in Victoria.”

A Wellington woman ended her life with Nembutal in 2006, after receiving advice on how to obtain it from Dr Nitschke. She was a life member of EXIT and was suffering from depression.
A woman died from Nembutal and presented their story as an affidavit in the Lecretia Seales case in May this year.

A South Island man known as John stated in 2009 that he intended to end his life using Nembutal. He was suffering from cancer.


Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anaesthesia.

Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis.

Barbiturate-induced sleep differs from physiological sleep. Sleep laboratory studies have demonstrated that barbiturates reduce the amount of time spent in the rapid eye movement (REM) phase of the sleep or dreaming stage. Also, Stages III and IV sleep are decreased. Following abrupt cessation of barbiturates used regularly, patients may experience markedly increased dreaming, nightmares, and/or insomnia. Therefore, withdrawal of a single therapeutic dose over 5 or 6 days has been recommended to lessen the REM rebound and disturbed sleep which contribute to drug withdrawal syndrome (for example, decrease the dose from 3 to 2 doses a day for 1 week).

In studies, secobarbital sodium and pentobarbital sodium have been found to lose most of their effectiveness for both inducing and maintaining sleep by the end of 2 weeks of continued drug administration at fixed doses. The short-, intermediate-, and, to a lesser degree, long-acting barbiturates have been widely prescribed for treating insomnia. Although the clinical literature abounds with claims that the short-acting barbiturates are superior for producing sleep while the intermediate-acting compounds are more effective in maintaining sleep, controlled studies have failed to demonstrate these differential effects. Therefore, as sleep medications, barbiturates are of limited value beyond short-term use.

Barbiturates have little analgesic action at subanesthetic doses. Rather, in subanesthetic doses, these drugs may increase the reaction to painful stimuli. All barbiturates exhibit anticonvulsant activity in anaesthetic doses. However, of the drugs in this class, only phenobarbital, mephobarbital, and metharbital have been clinically demonstrated to be effective as oral anticonvulsants in sub hypnotic doses. Email us at [email protected]



  1. Sedatives.
  2. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks (See “Clinical Pharmacology” section.)
  3. Preanesthetics.
  4. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. click here to contact